Aging process can be characterized as a spontaneous decrease of function in various organs with age. Muscle, as a big organ of human body, undergoes aging process presenting with loss of muscle mass, “sarcopenia”. Recently, several working groups have tried to make consensus about sarcopenia for definition and diagnosis. Muscle mass is known to be closely related with bone, brain, fat, cardiovascular and metabolic systems. With increased understanding, clinical and basic researches about sarcopenia have been also increased rapidly from various areas of health science and technology. In this paper, the history and recent concepts of sarcopenia were reviewed and brief discussion of its prospect in the field of neurosurgery was done.

Key Words : Aging · Muscles · Sarcopenia · Consensus · Stroke · Spine.

INTRODUCTION

We are living in the aging society with rapid increase of the proportion of aged population. Accordingly, geriatric syndrome became an important medicosocial issue recently. Muscle wasting is one of the main changes of aging human body, which was introduced by Rosenberg as the term sarcopenia in 1989. The loss of muscle mass is estimated about 8%/decade from 40 to 70 years of age, and then it becomes faster up to 15%/decade. Sarcopenia has been widely known to be the decreased mass and strength of skeletal muscle by an aging process, but there are still debates in its definition.

The European Union Geriatric Medicine Society (EUGMS) made a Sarcopenia Working Group, the European Working Group on Sarcopenia in Older People (EWGSOP), in 2009, and reported the European consensus on definition and diagnosis of sarcopenia in 2010. This European consensus seemed to trigger interest and attention for sarcopenia at many countries including Korea. The first annual meeting of Korean Sarcopenia Society was held at 2013. In 2014, the Asian consensus for sarcopenia was reported by the Asian Working Group for Sarcopenia (AWGS). There are several well-known operational definitions of sarcopenia based on skeletal muscle mass index (SMI), but the definition of EWGSOP combined both the quantitative factor (SMI) and qualitative factors (strength and function). The definitions are crucial for not only diagnosis but also treatment strategy of sarcopenia.

Sarcopenia is known to associate with various age related disorders, obesity, metabolic syndrome, cardiovascular disease, osteoporosis, and stroke. It already became hot topic for clinical and basic researches in the various medical fields like endocrinology, cardiology, rehabilitation medicine, and orthopedics. Most of the researchers are convincing the sarcopenia will make a tremendous and multidirectional impact on medical care system in the near future. But, most of neurosurgeons do not seem to have interests in the muscle condition which may have effects on clinical courses of some neurosurgical diseases.

In this paper, up-to-date information of sarcopenia is introduced with review of literature. The relationship of sarcopenia with neurosurgical disorders and the roles of neurosurgeons are also discussed.

DEFINITION AND DIAGNOSTIC ASSESSMENTS

Sarcopenia can be characterized by progressive loss of SMI and muscle strength with increasing risk of physical disability, poor quality of life, and sometimes death. There are several definitions based on muscle mass. The dual energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA) can be used for assessing SMI, and magnetic resonance imaging (MRI) and computerized tomography (CT) for muscle cross-sectional area (CSA).
The first reported definition of sarcopenia is based on DXA. DXA can measure the appendicular SM (ASM) at the fat free muscle mass of arm and leg. The definition of sarcopenia with DXA is the reduction of ASM/height less than or equal to two standard deviations (SD) comparing to the sex specific mean reference values of a young age (18–40 years) group.

SMMI measured by BIA can be used for definition of sarcopenia. Class I and II sarcopenia are defined as the SMMI less than one and two SD comparing to that of the sex specific mean reference value of young age (18–39 years) group, respectively.

CSA of muscle by MRI or CT is considered to be the most accurate data. The body weight (BW) corrected quadriceps (Qc) muscle CSA (Qc muscle CSA/BW) reflects thigh muscle mass. Qc sarcopenia can be defined as the BW corrected Qc muscle CSA more than 1 SD below the mean reference value of younger age (<60 years) group.

However, the muscle mass itself is not enough for diagnosis of sarcopenia because it is not correlated with its strength. The EWGSOP definition includes SMMI and muscle function, requiring 2 or 3 criteria among three diagnostic criteria (low muscle mass, low muscle strength, and low physical performance) for diagnosis of sarcopenia. The tools for assessing sarcopenia recommended by EWGSOP are CT, MRI, and DXA for muscle mass, grip strength for muscle strength, and short physical performance battery (SPPB) or gait speed for physical performance. SPPB score is total points of three tests, balance, gait speed, and chair stand, scoring between 0–4 for each test with maximum score of 12. Cut-off points for the three components differ according to the technique used for assessment. The cut-off points for SMMI measured with DXA are 7.26 kg/m² for men and 5.5 kg/m² for women by Baumgartner method, 7.23 kg/m² for men and 5.67 kg/m² for women by Newman method, and 7.25 kg/m² for men and 5.67 kg/m² for women by Delmonico method. Cut-off points for the muscle strength are <30 kg for men and <20 kg for women by Laurentani method or different muscle strength levels according to BMI introduced by Fried et al. Cut-off point for the physical performance is SPPB score ≤8 or gait speed <0.8 m/s. The EWGSOP-suggested diagnostic algorithm is started with the measurement of gait speed for the patient older than 65 years (Fig. 1: 1) With the gait speed >0.8 m/s, no sarcopenia is defined as the grip strength is normal, but SMMI should be measured as a final assessment for diagnosis of sarcopenia when the gait strength is subnormal, 2) With the gait speed ≤0.8 m/s, SMMI is the next step as a final assessment for diagnosis of sarcopenia.

The AWGS recommended cut-off points are SMMI <7.0 kg/m² for men and <5.4 kg/m² for women by DXA or <7.0 kg/m² for men and <5.7 kg/m² for women by BIA, handgrip strength <26 kg for men and <18 kg for women, and gait speed ≤0.8 m/s. The diagnostic algorithm of AWGS for sarcopenia starts with checking both handgrip strength and gait speed (Fig. 2). When the handgrip strength and/or gait speed less than cut-off points, then muscle mass is measured for diagnosis of sarcopenia.

Baumgartner et al. reported the prevalence of sarcopenia about 13–24% in the older patients (65–70 years) and increased up to 50% in the patients over 80 years of age, and it was higher in male group. Another study reported the prevalence of sarcopenia varies 6–15% in the subjects over 65 years of age with higher prevalence in male group. Sarcopenia also seemed to increase the rate of disability about 4.1 times and 3.6 times more in male and female groups comparing to the non-sarcopenic patients.

**PATHOPHYSIOLOGY**

Classically, skeletal muscle fibers are divided into two types, type 1 and 2. Type 1 fibers are known to be white muscle, fatigue resistant and slow fibers specialized for phasic contraction (e.g., marathon). Type 2 fibers are red muscle, faster and stronger than Type 1 fibers specialized for continuous contraction (e.g., weight lifting). The fatigue resistance of slow fibers related primarily with the use of oxidative metabolism by Type 1 fibers whereas glycolytic metabolism by Type 2 fibers. The Type 2 fibers are known to be the primary target for age related muscle atrophy. Varieties of factors, neurodegeneration, endocrinological environment, inflammatory dysfunction, and obesity have been proposed as the causes of sarcopenia.

The age related decrease in the number of motor neurons in spinal cord and peripheral nerve fibers and synaptic vesicles in neuromuscular junction had been reported to reduce SMMI.
Hormonal factors for maintaining muscular protein metabolism, growth hormone, insulin-like growth factor-1, corticosteroids, androgens, vitamin D, and insulin, are known to decrease with age influencing on SMI negatively\(^4,5,10,20,30,31,32\).

Some pro-inflammatory factors, interleukin-6 (IL-6), plasminogen activator inhibitor 1, and C-reactive protein, were reported to increase in plasma in the elderly people, which is closely related with the age related increase of body fat mass (adipokines)\(^33,42\). The low level inflammation by the increased pro-inflammatory factors with wasting of protein and energy seems to have effect on the sarcopenia in the elderly with obesity (sarcopenic obesity)\(^30,35,80\). Myokines, myogenic hormone like factors including IL-6, IL-8, IL-15, brain-derived neurotropic factor, and fibroblast growth factor-21, are known to increase during exercise showing protective effect in contrast to the harmful effect of adipokines for skeletal muscle\(^37,90,92\). IL-6 and IL-15 secreted from muscles are able to induce lipolysis of fat, so called “muscle-fat crosstalk”\(^76\).

Skeletal muscle can be regenerated through activation of satellite cells, undifferentiated mononuclear myogenic cells in skeletal muscles\(^91\). The satellite cells are known to be the adult stem cells of muscle, which tend to decrease in number and function with age\(^37,74\). According to previous reports, aged satellite cells show tendency to differentiate into adipose and fibrotic tissues\(^7,96\).

Myostatin, a member of transforming growth factor-beta family, can inhibit muscle growth\(^30\). Myostatin is thought to inhibit satellite cells proliferation according to previous studies about the relationship between myostatin level and satellite cell population in skeletal muscles\(^22,30\). Activin A is known to inhibit muscle growth through binding with type II activin receptor\(^22\). Both myostatin and activin A were also reported to inhibit bone mineralization by osteoblasts\(^20,22\). In contrast to the negative effect of myostatin and activin A on muscle and bone, follistatin can play a role of enhancing muscle growth and bone mineralization by antagonizing both myostatin and activin A\(^26,33\). Myostatin and activin A have been observed to increase with age, whereas follistatin did not show correlation with age\(^2,35,104\). The activin A-myostatin-follistatin system means the interactions among the three factors and seems to play an important role in both muscle growth and bone mineralization during aging process\(^4\). The terms “muscle-bone interaction” and “muscle-bone cross-talk” are hence proposed according to the concept that skeletal muscle and bone continuously affect and modulate each other's biological properties not only biomechanically but also endocrinologically\(^37,90\).

**OTHER SYNDROMES RELATED WITH SARCOPENIA**

**Sarcopenic obesity**

Sarcopenic obesity is the imbalance between muscle and fat mass, a combination of decreased SMI and increased visceral fat, in elderly people\(^200\). It is closely associated with reduced muscle strength and physical activity, metabolic disorders, and sometimes age related mortality\(^202,238,314\). In sarcopenic obesity, the decrease physical activity by muscle atrophy results in accumulation of body fat which will increase the levels of pro-inflammatory factors leading to muscle atrophy\(^8,97\). In addition, the muscle loss can induce metabolic disorders related with insulin resistance because skeletal muscle is the largest organ response to insulin\(^11,104\).

**Sarco-osteoporosis and osteosarcopenic obesity**

It seems that there are fragility fractures in the patients without osteoporosis according to BMD study or without high fracture risk calculated with World Health Organization fracture assessment tool\(^93,107\). The increased fracture risk with age seems to be greater than the age related reduction of BMD\(^90\). Recent studies revealed that patients with both osteoporosis and sarcopenia (sarco-osteoporosis) showed greater risk for fracture\(^13\). Buehring et al.\(^8\) reported the prevalences of sarcopenia, osteopenia, and sarco-osteopenia were about 15%, 17%, and 5% of the population with age ≥60 years.

Osteosarcopenic obesity was introduced by Ormsbee et al.\(^75\) in 2014 to define the individuals with obesity, low BMD, and sarcopenia. They said the obesity in addition to the pre-existing sarco-osteoporosis would exacerbate the metabolic disorders leading to poor physical function and quality of life. But there are still debates without conclusive diagnostic criteria for osteosarcopenic obesity even though it is one of the top emerging significant public health issues.

**Frailty**

Fried et al.\(^11\) first proposed definition for frailty in 2001 as an age related syndrome including weight loss, exhaustion, weakness of grip strength, slow walking speed, and low physical activity. Recent consensus for frailty definition is “a medical syndrome with multiple causes and contributors that is characterized by diminished strength, endurance and reduced physiologic function that increases an individual’s vulnerability for developing increased dependency and/or death”, which means sarcopenia combined with fatigue caused by many pathologic conditions\(^8,9,11\).

**Cachexia**

In 2008, Evans et al.\(^29\) introduced new definition of the cachexia, according to the agreement at the cachexia consensus conference, as a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. They proposed a multidimensional diagnostic assessment for cachexia including weight loss >5% for one year or BMI <20 with any three components of the followings: fatigue, anorexia, decreased muscle strength, anemia (hemoglobin <12 g/dL), hypoalbuminemia (<3.2 g/dL), or elevated inflammatory markers like IL-6 and C-reactive protein\(^90\). The major characteristics of cachexia comparing to sarcopenia are comorbid pathologic conditions (cancer, chronic heart failure, chronic obstructive pulmonary disease, etc.), decreased fat mass, systemic inflammation, increased protein wasting, increased resting energy expenditure, and anorexia\(^100\).
MANAGEMENT

Exercise
Most of studies for exercise therapy focused on progressive resistance training (PRT) to improve muscle strength and function rather than aerobic exercise. Yarasheski et al. recommended PRT for elderly population (76–92 years), 3 days/week for 3 months. They reported increase of whole body muscle mass about 2.2 kg for men and 1.0 kg for women. Gate speed and muscle strength were also known to be improved with PRT.

Nutrition
Sarcopenic elderly individuals are recommended to intake protein of 1.0–1.5 g/kg/day which is about 15–20% of daily caloric intake. Supplementary Vitamin D (700 IU/day) is recommended for the patients with vitamin D level <100 nmol/L. Creatine monohydrate is also known to helpful for energy storage by increasing availability of phosphocreatine. Chrusch et al. reported creatine supplement with PRT increased muscle mass as well as improved muscle strength.

Anabolic therapies
Testosterone and growth hormone had been reported to increase muscle mass and strength in elderly patients. But it needs more clinical trials to prove evidence as a treatment for sarcopenia.

SARCOPENIA AND NEUROSURGICAL CONDITIONS

Cerebrovascular disease
Motor paralysis induces early changes in muscle tissue by decreased motor nerve signals and reduction of number of motor units. During chronic phase after stroke, disuse and spasticity can result in muscle atrophy and muscle type shift. The distribution of muscle fiber types also changes after stroke from type 1 slow twitch muscle fibers to type 2 fast twitch muscle fibers, which is an inverse direction of age related muscle fiber type shift. The muscle type shift after stroke was reported to affect clinical result negatively by aggravating gait disturbance with decreased walking speed of paralyzed leg. Malnutrition is a common problem affecting clinical outcome of stroke patients, and it also affect the development of sarcopenia.

Despite the negative influences of sarcopenia on the prognosis of stroke, guidelines for treatment, prevention, and rehabilitation of stroke patients do not indicate any consideration about stroke related sarcopenia. Sarcopenia seems to be overlooked during management of patients after stroke.

Spine
Muscles consist of major portion of spine, but spine surgeons seem to not well understand the nature of muscles around spine comparing to that of bone, joint, or spinal nerves. Osteoporosis is one of the leading problems of spine in the elderly population, and is known to be closely related with sarcopenia through muscle-bone cross-talk. There are strong evidences that muscular atrophy and fat infiltration are the representative age related degenerative changes of muscles. Both the atrophy and fatty change of paraspinal muscles are also known to be associated with functional disorders and chronic back pain. Degenerative lumbar spinal deformities including flat back syndrome and degenerative lumbar kyphosis are also reported to associate with paraspinal muscular atrophy and fatty change.

In spite of many evidences for the relationship between paraspinal muscular atrophy and spinal disorders, there is still lack of concept to link the spinal problems with sarcopenia. The main reason of this mismatch may come from the definition of sarcopenia as a systemic disorder.

CONCLUSIONS

Muscles seem to have been underestimated in relation to the neurosurgical disorders. Even though sarcopenia is not yet listed in the 2014 release of international classification of disease, it must be an essential part of clinical practice and research by neurosurgeons in the near future.

References
1. Arasaki K, Igarashi O, Ichikawa Y, Machida T, Shirouzu I, Hyodo A, et al. Reduction in the motor unit number estimate (MUNE) after cerebral infarction. J Neurol Sci 250: 27-32, 2006
2. Baccarelli A, Morpurgo PS, Corsi A, Vaghi I, Fanelli M, Cermonesi G, et al. Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects. Exp Gerontol 36: 1403-1412, 2001
3. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147: 755-763, 1998
4. Binkley N, Buehring B. Beyond FRAX: it’s time to consider “sarco-osteopenia”. J Clin Densitom 12: 413-416, 2009
5. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, et al.: Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339: b3692, 2009
6. Bowser M, Herberg S, Arounleut P, Shi X, Fulzele S, Hill WD, et al.: Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp Gerontol 48: 290-297, 2013
7. Brack AS, Conboy MJ, Roy S, Lee M, Xiao CJ, Keller C, et al.: Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 317: 807-810, 2007
8. Buehring B, Kruger D, Binkley N: Effect of including historical height and radius BMD measurement on sarco-osteoporosis prevalence. J Gerontol A Biol Sci Med Sci 64: 1344-1349, 2009
9. Campion DR, Richardson RL, Reagan JD, Kraeling RR: Changes in the satellite cell population during postnatal growth of pig skeletal muscle. J Anim Sci 52: 1014-1018, 1981
10. Candow DG, Chilibeck PD: Effect of creatine supplementation during resistance training on muscle accretion in the elderly. J Nutr Health Aging 11: 185-188, 2007
11. Carda S, Cisari C, Invernizzi M: Sarcopenia or muscle modifications in neurologic diseases: a lexical or pathophysiological difference? Eur J Physiol
Sarcopenia and Neurosurgery | SW Park

Rehabil Med 49: 119-130, 2013
12. Carlson CJ, Booth FW, Gordon SH: Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloadning. Am J Physiol 277 (2 Pt 2): R601-R606, 1999
13. Cesarri M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW, Lindahl L, et al.: Sarcopenia, obesity, and inflammation—results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr 82: 428-434, 2005
14. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyai KS, et al.: Sarcopenia in Asia: consensus report of the asian working group for sarcopenia. J Am Med Dir Assoc 15: 95-101, 2014
15. Choi KM: Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul) 28: 86-89, 2013
16. Chrusciel MJ, Chalibek PD, Chad KE, Davison KS, Burke DG: Creatine supplementation combined with resistance training in older men. Med Sci Sports Exerc 33: 2111-2117, 2001
17. Cianfrootti L, Brandi ML: Muscle-bone interactions: basic concepts and clinical aspects. Endocrine 45: 165-177, 2014
18. Clark BC, Marini TM: Sarcopenia is dynapenia. J Gerontol A Biol Sci Med Sci 63: 829-834, 2008
19. Coin A, Perissinotto E, Enzi G, Zamboni M, Inelmen EM, Frigo AC, et al.: Predictors of low bone mineral density in the elderly: the role of dietary intake, nutritional status and sarcopenia. Eur J Clin Nutr 62: 802-809, 2008
20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al.: Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39: 412-423, 2010
21. De Deyne PG, Hafer-Macko CE, Ivey FM, Ryan AS, Macko RF: Muscle molecular phenotype after stroke is associated with gait speed. Muscle Nerve 30: 209-215, 2004
22. Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, et al.: Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 55: 769-774, 2007
23. DiGironamo DJ, Kiel DP, Esser KA: Bone and skeletal muscle: neighbors with close ties. J Bone Miner Res 28: 1509-1518, 2013
24. Doherty TJ, Vandervoort AA, Brown WF: Effects of aging on the motor unit: a brief review. Can J Appl Physiol 18: 331-358, 1993
25. Drummond MJ, Dreyer HC, Pennings B, Fry CS, Dhanani S, Dillon EL, et al.: Skeletal muscle protein anabolic response to resistance exercise and essential amino acids is delayed with aging. J Appl Physiol (1985) 104: 1452-1461, 2008
26. Eijkm M, Swagemakers S, Koerdam M, Steenbergen C, Derlek P, Uitterlinden AG, et al.: The activin-A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 21: 2949-2960, 2007
27. Elkasrawy MN, Hamrick MW: Myostatin (GDF-3) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact 10: 56-63, 2010
28. Evans WJ, Campbell WW: Sarcopenia and age-related changes in body composition and functional capacity. J Nutr 123 (2 Suppl): 465-468, 1993
29. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al.: Cachexia: a new definition. Clin Nutr 27: 793-799, 2008
30. Faustone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ: High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 263: 3029-3034, 1990
31. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottlieber J, et al.: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146-M156, 2001
32. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al.: Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42: 2276-2276, 2011
33. Gilson H, Schakman EM, Kalista S, Lause P, Tischkova K, Thissen JP: Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activins. Am J Physiol Endocrinol Metab 297: E157-E164, 2009
34. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, et al.: The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci 61: 1059-1064, 2006
35. Grimby G, Salih B: The ageing muscle. Clin Physiol 3: 209-218, 1983
36. Guralnik JM, Ferrucci L, Pepe CE, Leveille SG, Markides KS, Ostir GV, et al.: Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci 55: M221-M231, 2000
37. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al.: A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality in older people. J Gerontol 49: M85-M94, 1994
38. Guth L, Samaha FJ: Qualitative differences between actomyosin ATPase of slow and fast mammalian muscle. Exp Neurol 25: 138-152, 1969
39. Hamrick MW: The skeletal muscle secretome: an emerging player in muscle-bone crosstalk. Bonekey Rep 1: 60, 2012
40. Hikida RS: Aging changes in satellite cells and their functions. Curr Aging Sci 4: 279-297, 2011
41. Hoffman JR, Kravemr WJ, Bhasin S, Storer T, Ratamess NA, Haff GG, et al.: Position stand on androgen and human growth hormone use. J Strength Cond Res 23 (5 Suppl): S1-S59, 2009
42. Honda H, Qureshi AR, Axelsson J, Heimburger O, Suliman ME, Barany P, et al.: Osteosarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr 86: 633-638, 2007
43. Hyun SJ, Bae CW, Lee SH, Rihm SC: Fatty degeneration of paraspinal muscle in patients with the degenerative lumbar kyphosis: a new evaluation method of quantitative digital analysis using MRI and CT scan. J Spinal Disord Tech 2013 [Epub ahead of print]
44. Hyun SJ, Kim YB, Kim YS, Park SW, Nam TK, Hong HJ, et al.: Post-operative changes in paraspinal muscle volume: comparison between paramedian interfascial and midline approaches for lumbar fusion. J Korean Med Sci 22: 646-651, 2007
45. Inouye SK, Studenski S, Tinetti ME, Kuchel GA: Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 55: 780-791, 2007
46. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R: Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol 159: 413-421, 2004
47. Janssen I, Heymsfield SB, Ross R: Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50: 889-896, 2002
48. Kelly TL, Wilson KE, Heymsfield SB: Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One 4: e7038, 2009
49. Kim TN, Park MS, Lim KL, Choi HY, Yang SJ, Yoo HJ, et al.: Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf) 78: 525-532, 2013
50. Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, et al.: Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KOSO). Diabetes Care 33: 1497-1499, 2010
51. Kim TN, Yang SJ, Yoo HJ, Lim KL, Kang HJ, Song W, et al.: Prevalence of
sarcopenia and visceral obesity are risk factors for postural instability in the middle-aged to elderly population. *Geriatr Gerontol Int* **10**: 233-243, 2010

73. Ormsbee MJ, Prado CM, Ilich JZ, Purcell S, Siervo M, Folsom A, et al.: Osteosarcopenic obesity: the role of bone, muscle, and fat on health. J *Cachexia Sarcopenia Muscle* 2014 [Epub ahead of print]

74. Pannieré A, Marazza G, Sasso D: Stem cells in the hood: the skeletal muscle niche. *Trends Mol Med* **18**: 599-606, 2012

75. Pedersen BK: 'The diseasome of physical inactivity—and the role of myokines in muscle–fat cross talk. *J Physiol* **587** (Pt 23): 5559-5568, 2009

76. Pedersen BK, Edward F: Adipokine distinguished lecture: muscle as an endocrine organ: IL-6 and other myokines. *J Appl Physiol* **(1985)** 107: 1006-1014, 2009

77. Peter JB, Barnard RJ, Edgerton VR, Gillespie CA, Stempel KE: Metabolic profiles of three fiber types of skeletal muscle in guinea pigs and rabbits. *Biochemistry* **11**: 2627-2633, 1972

78. Quinn TJ, Paolucci S, Sunnernhagen KS, Svenius J, Walker ME; Tonic D, et al.: Evidence-based stroke rehabilitation: an expanded guidance document from the European stroke organisation (ESO) guidelines for management of ischaemic stroke and transient ischaemic attack 2008. *J Rehabil Med* **41**: 99-111, 2009

79. Rosenberg IH: Sarcopenia: origins and clinical relevance. *Clin Geriatr Med* **27**: 337-339, 2011

80. Rosenberg IH: Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. *Am J Clin Nutr* **50**: 1231-1233, 1989

81. Roubenoff R: 'Catabolism of aging: is it an inflammatory process? *Carr Opin Clin Nutr Metab Care* **6**: 295-299, 2003

82. Roubenoff R: Sarcopenic obesity: the confluence of two epidemics. *Obes Res* **12**: 887-888, 2004

83. Ryan AS, Nicklas BJ: Age-related changes in fat deposition in mid-thigh muscle in women: relationships with metabolic cardiovascular disease risk factors. *Int J Obes Relat Metab Disord* **23**: 126-132, 1999

84. Sato K, Iimatsu M, Aizawa K, Ajsaka R: Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle. *Am J Physiol Endocrinol Metab* **294**: E961-E968, 2008

85. Sayer AA, Syddall HE, Dennison EM, Martin LJ, Phillips DI, Cooper C, et al.: Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. *QJM* **100**: 707-713, 2007

86. Scherbakov N, van Eijling S, Anker SD, Bierhaus A, Doehner W: Stroke induced Sarcopenia: muscle wasting and disability after stroke. *Int J Cardiol* **170**: 89-94, 2013

87. Schrager MA, Metter EJ, Simonsick E, Bile A, Bandinelli S, Lauretani F, et al.: Sarcopenic obesity and inflammation in the InCHIANTI study. *J Appl Physiol* **(1985)** 102: 919-925, 2007

88. Scheltinga MA, Rantanen T, Hekkinga S, Koskinen S: The mediating role of C-reactive protein and handgrip strength between obesity and walking limitation. *J Am Geriatr Soc* **56**: 462-469, 2008

89. Tan BH, Fearon KC: Cachexia: prevalence and impact in medicine. *Curr Opin Clin Nutr Metab Care* **11**: 400-407, 2008

90. Taylor-Jones JM, McGehee RE, Tan BH, Lecka-Czernik B, Lipschitz DA, Peterson CA: Activation of an adipogenic program in adult myoblasts with age. *Mech Ageing Dev* **123**: 649-661, 2002

91. Theou O, Jones GR, Overend TJ, Kloosch M, Vandervoort AA: An exploration of the association between frailty and muscle fatigue. *Appl Physiol Nutr Metab* **33**: 651-665, 2008

92. Visser M, Deeg DJ, Lips P: Longitudinal Aging Study Amsterdam: Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. *J Clin Endocrinol Metab* **88**: 5766-5772, 2003

93. Vlasiopoulos A, Combet E, Lean ME: Changing distributions of body size and adiposity with age. *Int J Obes (Lond)* **38**: 857-864, 2014
94. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90: 2787-2793, 2005
95. Walsh K: Adipokines, myokines and cardiovascular disease. Circ J 73: 13-18, 2009
96. Wang ZM, Visser M, Ma R, Baumgartner RN, Kotler D, Gallagher D, et al.: Skeletal muscle mass: evaluation of neutron activation and dual-energy X-ray absorptiometry methods. J Appl Physiol (1985) 80: 824-831, 1996
97. Watts NB: The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice. J Womens Health (Larchmt) 20: 525-531, 2011
98. Wehling M, Cai B, Tidball JG: Modulation of myostatin expression during modified muscle use. FASEB J 14: 103-110, 2000
99. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE: Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 58: 618-625, 2003
100. Working Group on Functional Outcome Measures for Clinical Trials: Functional outcomes for clinical trials in frail older persons: time to be moving. J Gerontol A Biol Sci Med Sci 63: 160-164, 2008
101. Yarasheski KE, Pak-Loduca J, Hasten DL, Obert KA, Brown MB, Simacore DR: Resistance exercise training increases mixed muscle protein synthesis rate in frail women and men >/=76 yr old. Am J Physiol 277 (1 Pt 1): E118-E125, 1999
102. Yoo SH, Kim JS, Kwon SU, Yun SC, Koh JY, Kang DW: Undernutrition as a predictor of poor clinical outcomes in acute ischemic stroke patients. Arch Neurol 65: 39-43, 2008
103. Zadik Z, Chalew SA, McCarter RJ Jr, Meistas M, Kowarski AA: The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 60: 513-516, 1985
104. Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V: Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis 18: 388-395, 2008